Cambridge Heart, Inc. (NASDAQOTCBB:CAMH)

CAPS Rating: No stars

The Company is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease.

Results 1 - 8 of 8

Recs

0
Member Avatar WindRules (< 20) Submitted: 6/15/2007 5:56:33 PM : Outperform Start Price: $4.43 CAMH Score: -142.26

Good product.
Numbers: -.16 this year, projected +.13 next year
PE from -28.26 to +33.69.
marketwatch
Their site: Increase in revenue from first quarter 2006 to first quarter 2007: 83%

Recs

1
Member Avatar paulmacdo (< 20) Submitted: 4/28/2007 11:58:18 AM : Outperform Start Price: $3.36 CAMH Score: -146.34

This technology will become the standard for determining whether defibs are needed or not. Major clinical trials all support this. Another larege clinical trial is due in Nov, 2007. Insurance coverage already in place and more to come. Recent marketing colaboration with STJ is going to propel sales and adoption. NASDAQ listing will also add to PPS appreciation. CAMH will explode over the 2 years.

Recs

0
Member Avatar aircarp (< 20) Submitted: 3/30/2007 10:26:31 PM : Outperform Start Price: $3.18 CAMH Score: -154.04

MTWA test now mandatory for Medicare and half of US insured prior to implant of an ICD.

New Sales and Marketing relationship with St. Jude (STJ). 2000 experienced and connected sales professionals will soon be selling the product.

FDA Approved. Patent Holder with mo Competition.

$120M+ Revenue target with 50-65% Margin = $25+ stock over next 2 years.

Recs

0
Member Avatar obiwankenobe1250 (86.46) Submitted: 3/22/2007 3:20:15 PM : Outperform Start Price: $3.23 CAMH Score: -153.00

Like the news...

Recs

0
Member Avatar gitau4ever (42.71) Submitted: 3/22/2007 1:17:44 PM : Underperform Start Price: $3.22 CAMH Score: +152.79

What goes up.. must come down!

Recs

0
Member Avatar plaidone (98.54) Submitted: 2/1/2007 12:46:46 PM : Underperform Start Price: $2.58 CAMH Score: +152.37

TMFBent pick.

Recs

1
Member Avatar mdinvestor (< 20) Submitted: 1/17/2007 4:05:24 PM : Outperform Start Price: $2.21 CAMH Score: -153.36

Exclusive technology, best data, impending media blitz regarding sudden death by MDT. Defib. companies now realize that MTWA adoption will increase number of defib. implanted.

Impending paradigm shift in this branch of medicine. Pull back due to stockprice getting ahead of itself. Good entry point here.

Goodluck!

Recs

7
Member Avatar SteadySaber (65.59) Submitted: 12/31/2006 7:19:24 PM : Underperform Start Price: $2.77 CAMH Score: +154.49

I spoke with a few doctors and they pointed out that the ultimate users and buyers of this equipment have a disincentive to use it because they make more money installing the defibs and therefore don't want to find out what patients will not benefit from the defibs. Moreover, the cost of the machine is so high that only groups of 30-50 can afford to make the purchase and these groups I'm told only conduct a few tests a week. If hospitals start buying it for the cardios then that may change the limitations to some extent. Bottom line, this stock has a huge cult following and therefore I think is overly hyped as is what typically happens in the market. Once reality sets in, they will not be able to sell nearly as many of these equipment as people think. This is one to watch AFTER some decent sales start happening and not before. All the

Results 1 - 8 of 8

Featured Broker Partners


Advertisement